Celadon Pharmaceuticals Plc’s CEO Jim Short featured discussing the new MHRA framework for UK domestic production of cannabis-based medicines. Celadon was proudly a pioneer in working with the regulators back in 2019-2020.
The new framework indicates a truly pharmaceutical direction of travel for the UK. This is Celadon’s approach: pharma-grade products, breakthrough R&D and clinical trials.
Read more over at BusinessCann by clicking here.